Alan C Rigby

Title: Alan C Rigby: Innovator in Targeted Cancer Therapy

Introduction

Alan C Rigby is a notable inventor based in Glen Ridge, NJ (US). He has made significant contributions to the field of oncology through his innovative work on targeted therapies. His research focuses on developing compounds that interact with specific cellular receptors, paving the way for more effective cancer treatments.

Latest Patents

Alan C Rigby holds a patent for "Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatment." This invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates are designed to deliver a powerful cytotoxin inside the cell, offering significant advantages over other known conjugates. They provide targeted tumor therapy and bystander activity to neighboring cells, which is crucial for treating tumors with moderate receptor expression.

Career Highlights

Throughout his career, Alan has worked with prominent companies in the biotechnology sector, including Imclone LLC and Immunogen, Inc. His experience in these organizations has allowed him to refine his expertise in drug development and targeted therapies.

Collaborations

Alan has collaborated with notable professionals in his field, including Paul J Balderes and Scott W Eastman. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Alan C Rigby is a distinguished inventor whose work in targeted cancer therapies has the potential to transform treatment options for patients. His innovative approach to drug delivery systems highlights the importance of precision medicine in oncology.